Illumina says it had expected EU hold order on Grail By Reuters
BRUSSELS (Reuters) – U.S. life sciences company Illumina (NASDAQ:) said on Monday that it had anticipated an order from EU antitrust enforcers to keep recently acquired Grail as a separate company while waiting for regulatory clearance of the deal.
In the days ahead, the company stated that it will discuss the European Commission’s suggestions. Although the EU competition enforcer earlier Monday stated it planned to take interim steps against the company in the wake of the closing prematurely, it did not give details.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.